hematological cancers

Peptide Targeting: Solid Tumors vs Blood Cancers

Peptide designs for solid tumors focus on penetrating dense extracellular matrices and resisting harsh microenvironments, while those for hematological cancers prioritize rapid binding in circulation and evasion of clearance mechanisms. Accessibility defines the core challenge: solid tumors act as fortified structures with poor blood supply, unlike freely circulating blood cancer cells. These differences shape peptide length, stability features, and conjugation methods, with no universal approach suiting both.